US law makers gearing up for a real scrap with dealmakers!

The recent publication of the Panama papers, combined with the US government calling off the USD 160bn Pfizer/Allegan deal amid tax inversion rule changes, mean dealmakers look likely to face a number of small term challenges.

Pfizer/Allergan deal “inversion” deal catches the eye of US politicians

This week’s announcement of the USD 160bn deal between Pfizer and Allegan has already attracted criticism from US politicians. Given that Republicans and Democrats seem to agree on the issue, could it be something they will try to include in their 2016 campaign pitches?